ApoB — research review 2

...and this brings us to ApoB. It's often highlighted in longevity circles, but let's break down what the human evidence actually shows.

Right. ApoB isn't a molecule you take; it’s a measurement. It quantifies the atherogenic particle count in your blood, and it's causally linked to heart disease. High ApoB means higher risk. This is well-established from Mendelian randomization studies, for instance, a 2017 paper in JAMA Cardiology.

Absolutely. So, when people talk about "optimizing ApoB," they're usually referring to interventions that lower this particle count. Statins are a prime example, shown repeatedly in massive clinical trials like the JUPITER trial (2008, NEJM) to significantly reduce cardiovascular events, partly through lowering ApoB.

And that’s a key distinction: statins have robust human trial data for outcome improvement. But what about all the other compounds marketed for longevity? Many supplements claim to support cardiovascular health.

Precisely. For most of these, we simply don’t have the equivalent large-scale, long-term human outcome trials demonstrating a direct reduction in cardiovascular events or even a consistent, significant lowering of ApoB that translates to better health. Many studies are small, short-term, or focus on surrogate markers without proving actual clinical benefit.

So, while some may show small shifts in markers, the causal link to human outcomes for many popular supplements is still unproven, unlike with established interventions like statins. It's crucial to differentiate between a theoretical mechanism and robust human clinical evidence.